Get started
Author

Lynn Tomsho

The Amborella Genome and the Evolution of Flowering Plants
2013 · Amborella Genome Project, Victor A. Albert, et al. · Science · 874
Sputum microbiome temporal variability and dysbiosis in chronic obstructive pulmonary disease exacerbations: an analysis of the COPDMAP study
2017 · Zhang Wang, Richa Singh, et al. · Thorax · 142
PDF
The Founder Mutation MSH2*1906G→C Is an Important Cause of Hereditary Nonpolyposis Colorectal Cancer in the Ashkenazi Jewish Population
2002 · W.D. Foulkes, I. Thiffault, et al. · The American Journal of Human Genetics · 133
PDF
Unusual combinatorial involvement of poly-A/T tracts in organizing genes and chromatin in Dictyostelium
2012 · Gue Su Chang, Angelika A. Noegel, et al. · Genome Research · 33
PDF
In Vitro Activity and Microbiological Efficacy of Gepotidacin from a Phase 2, Randomized, Multicenter, Dose-Ranging Study in Patients with Acute Bacterial Skin and Skin Structure Infections
2019 · Nicole E. Scangarella-Oman, Karen A. Ingraham, et al. · Antimicrobial Agents and Chemotherapy · 18
Immune signaling mediates stromal changes to support epithelial reprogramming in celiac duodenum
2025 · Dylan Richards, Klebea Sohn, et al. · Cell Reports · 9
DOP53 Clinical, endoscopic, histological and biomarker activity following treatment with the gut-selective, pan-JAK inhibitor TD-1473 in moderately to severely active ulcerative colitis
2019 · W Sandborn, D Nguyen, et al. · Journal of Crohn s and Colitis · 6
PDF
Multiomic characterisation of the clinical efficacy of guselkumab induction therapy in ulcerative colitis
2026 · Amy Hart, Sunandini Sridhar, et al. · BMJ Open Gastroenterology · 3
PDF
A randomized, double-blind, placebo-controlled, single- and multiple-dose phase 1 study of VE202, a defined bacterial consortium for treatment of inflammatory bowel disease: safety and colonization dynamics of a novel live biotherapeutic product in healthy adults
2025 · Jeffrey L. Silber, Jason M. Norman, et al. · European Journal of Gastroenterology & Hepatology · 2
OP29 Icotrokinra, the first targeted oral peptide that selectively blocks the interleukin-23 receptor, reduces systemic and tissue inflammatory burden in Ulcerative Colitis: Results from the ANTHEM-UC study
2026 · E Louis, V Jairath, et al. · Journal of Crohn s and Colitis · 1
801 – Clinical, Endoscopic, Histologic and Biomarker Activity Following Treatment with the Gut-Selective, Pan-Jak Inhibitor Td-1473 in Moderately-To-Severely Active Ulcerative Colitis
2019 · William J. Sandborn, Deanna Nguyen, et al. · Gastroenterology · 1
PDF
P849 Genetic variation within the NKG2D pathway may influence the response to anti-NKG2D therapy in Crohn’s disease
2018 · A Hart, E Neiman, et al. · Journal of Crohn s and Colitis · 1
Protocol for isolating cells from a single cryopreserved gastrointestinal endoscopic biopsy for single-cell RNA sequencing
2026 · Daniel Horowitz, Joshua Rusbuldt, et al. · STAR Protocols
27 Icotrokinra, the First Targeted Oral Peptide That Selectively Blocks the Interleukin-23 Receptor, Reduces Systemic and Tissue Inflammatory Burden in Ulcerative Colitis: Results From the Anthem-uc Study
2026 · Edward V. Loftus, Vipul Jairath, et al. · Gastroenterology
27 Icotrokinra, the First Targeted Oral Peptide That Selectively Blocks the Interleukin-23 Receptor, Reduces Systemic and Tissue Inflammatory Burden in Ulcerative Colitis: Results From the Anthem-uc Study
2026 · Edward V. Loftus, Vipul Jairath, et al. · Gastrointestinal Endoscopy
OP36 A colonic gene expression signature predicts non-response to anti-inflammatory therapies in inflammatory bowel disease
2019 · T Sato, K Li, et al. · Journal of Crohn s and Colitis
Works count: 17
Citation count: 2,097
H-index: 7
I10-index: 6
Year
Topic
Type